One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder
Authors:
- on behalf of the “Lombardy ADHD Registry Group”OGon behalf of the “Lombardy ADHD Registry Group”
- Maurizio BonatiMBMaurizio Bonati
- 3 May 2011
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 67 (10) , 1061-1067
Abstract
Objectives To delineate the safety and tolerability profile of methylphenidate and atomoxetine in children and adolescents with attention deficit hyperactivity disorder (ADHD) monitored for more than 1 year. Design A cohort study analyzing data from the national ADHD register on patients from the Lombardy Region treated with MPH or atomoxetine. Participants A total of 229 children (median age 11 years, range 6–17), enrolled in 15 regional centers between June 2007 and May 2010. Results The prevalence rate of pharmacological treatment for ADHD was 0.23%, whereas the estimated ADHD prevalence in the population was 0.95%. In total, 73.8% of patients had been treated with atomoxetine (10–90 mg daily) or MPH (10–75 mg daily); 22% of patients also received an additional psychotropic drug. Of the treated children, 26.9% discontinued the drug prior to 1 year of treatment, mostly because of adverse effects (28.6%). No new or unexpected adverse events (rate 39.2%) were encountered. Decreased appetite, headache, and unstable mood were the leading events. The most severe events occurred in two boys: one experienced absence seizures for the first time with MPH, the other experienced hallucinations with atomoxetine. Therapy was discontinued in ten male patients (7.7%) because of adverse events. All patients with adverse effects recovered well. Conclusions A very low rate of ADHD prevalence was estimated in Italian children compared to that reported in other countries. Although the medications for ADHD are generally well tolerated, with only mild or minor adverse effects in most cases, their rational use can only be guaranteed by disseminating and monitoring evidence-based practices and by monitoring the safety and efficacy of treatments in both the short and long terms with appropriate tools and approaches.Keywords
This publication has 25 references indexed in Scilit:
- European guidelines on managing adverse effects of medication for ADHDEuropean Child & Adolescent Psychiatry, 2010
- Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the NetherlandsCurrent Medical Research and Opinion, 2010
- Cardiovascular safety of ADHD medications: rationale for and design of an investigator‐initiated observational studyPharmacoepidemiology and Drug Safety, 2010
- Cardiovascular Effects of Medications for the Treatment of Attention-Deficit Hyperactivity DisorderPediatric Drugs, 2010
- Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and AdultsCNS Drugs, 2009
- Attention‐Deficit‐Hyperactivity Disorder: An UpdatePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009
- The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite StudyJournal of the American Academy of Child & Adolescent Psychiatry, 2009
- Review of ADHD Pharmacotherapies: Advantages, Disadvantages, and Clinical PearlsJournal of the American Academy of Child & Adolescent Psychiatry, 2009
- Beyond polemics: science and ethics of ADHDNature Reviews Neuroscience, 2008
- Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity DisorderCirculation, 2008